CGRP Migraine Preventives: Why the New Injections Work When Pills Didn't

Migraine is far more than a bad headache. It is a disabling neurological condition that affects nearly 1 in 5 US adults, and for years the drugs used to prevent it were borrowed from other conditions — beta-blockers, antidepressants, antiseizure agents — with mixed results and real side effects. A new class targets migraine at its source. This guide explains what CGRP preventives are, how they differ from the old options, and what the current evidence says about who benefits.

Key Takeaways

• CGRP-targeted therapies are now considered first-line preventive options for migraine, not a last resort after older drugs fail (American Headache Society, 2024).
• Four monthly injection antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and oral daily gepants (atogepant, rimegepant) are FDA-approved for prevention.
• Tolerability is the headline advantage: older nonspecific preventives were adhered to by only about 17% of users at one year, a major reason people stop.
• These drugs reduce migraine days but rarely erase them; they are prevention, not abortive rescue for an attack already in progress.

How Do CGRP Migraine Preventives Actually Work?

Calcitonin gene-related peptide (CGRP) is a neurotransmitter that widens blood vessels and drives pain signaling during a migraine attack. CGRP-targeted therapies block that pathway either with a monoclonal antibody that binds CGRP or its receptor, or with a small-molecule "gepant" that blocks the receptor (American Headache Society, 2024). This is the first set of drugs designed specifically for migraine rather than repurposed from other conditions.

The practical difference shows up in how they are taken. The four antibodies are given as a monthly subcutaneous injection (or, for eptinezumab, a quarterly IV infusion). The gepants atogepant and rimegepant are oral tablets taken daily or every other day. For someone who fears needles, the oral gepants close the gap the American Headache Society flagged when it noted patients value oral over injectable routes.

Evidence capsule: A 2026 network meta-analysis of 26 randomized controlled trials including 17,620 participants found CGRP monoclonal antibodies and oral gepants showed consistent, durable efficacy and excellent tolerability for migraine prevention, with most trials rated low risk of bias (Neurology, 2026).

Why Are These Considered First-Line Now Instead of Last Resort?

Older preventive drugs — amitriptyline, propranolol, topiramate, valproate — work for some people but carry sedation, weight change, cognitive fog, or birth-defect risks that erode adherence. The American Headache Society's 2024 position statement explicitly named CGRP-targeting therapies as a first-line option and said initiation should not require failing two older drugs first.

The reason is tolerability. In its response to competing guidance, the AHS noted that poor tolerability is a primary reason for low adherence to nonspecific therapies, by some measures only 17% at one year. A drug that prevents migraine but is abandoned after three months helps no one. CGRP agents are better tolerated, which is why specialists now lead with them for appropriate patients.

CGRP Injections vs Gepant Pills: Which Should You Consider?

The choice is less about raw efficacy and more about fit. Both antibody injections and oral gepants are FDA-approved for episodic and chronic migraine prevention (American Headache Society, 2024). A few factors shape the decision:

• Needle tolerance: If injections are a nonstarter, oral gepants (atogepant, rimegepant) provide a non-injectable path.
• Onset and frequency: Antibodies are once monthly (or quarterly IV); gepants are daily or every-other-day pills.
• Cost and coverage: CGRP therapies are substantially more expensive than generic beta-blockers or amitriptyline, and coverage varies by plan (American Headache Society, 2025).
• Other medications: People already on multiple drugs may prefer one monthly injection over another daily pill.

For a closer look at how everyday triggers intersect with treatment, see our caffeine and anxiety limits. And before acting on any online health claim, our guide to asking AI about health safely covers verification steps.

What Does the Evidence Show About Real-World Effectiveness?

CGRP therapies reduce monthly migraine days and improve quality of life, and they work in people who previously failed multiple other preventives — a group where older drugs often fall short (American Headache Society, 2024). They are prevention: taken routinely to lower attack frequency, not used to stop a migraine that has already started (abortive drugs like triptans or gepants-as-needed handle that).

A 2026 real-world claims study of galcanezumab versus traditional preventive medication found meaningful reductions in monthly headache days and severity over 24 months, reinforcing that benefit persists beyond the short pivotal trials (Neurology and Therapy, 2025). No treatment eliminates every attack, and response varies person to person.

Who Should Not Use CGRP Preventives?

These are prescription drugs with real considerations. Erenumab has a warning related to hypersensitivity and, rarely, constipation that can be severe. Gepants carry caution in people with severe liver impairment (for some agents) and are not for use during pregnancy outside clinician guidance. Cost and access remain real barriers, and they are not abortive treatments for an active attack.

This list is not exhaustive. A clinician should confirm suitability based on your full history, other medications, and whether you need prevention versus rescue. If cost is the blocker, our strategies for unaffordable prescriptions may help open the conversation with your prescriber.

Frequently Asked Questions

Are CGRP shots safe for long-term use?

The longest trials now extend past three years and show a consistent safety profile (American Headache Society, 2024). The most common issues are injection-site reactions and, for some antibodies, mild constipation or (with certain agents) conjunctivitis. Discuss any new or persistent symptom with your clinician.

Will insurance cover a CGRP preventive?

Coverage varies widely. CGRP therapies cost substantially more than generic preventives, and prior authorization is common (American Headache Society, 2025). Confirm your plan's formulary and ask about manufacturer copay programs.

Do these replace my abortive migraine pills?

No. CGRP preventives lower how often attacks happen; they are not designed to stop a migraine already in progress. Triptans, NSAID formulations, or as-needed gepants remain the rescue tools for active attacks, per your clinician's plan.

How fast do CGRP preventives work?

Many people see reduced migraine days within the first 4 to 12 weeks, which aligns with the standard efficacy assessment window used in pivotal trials (American Headache Society, 2024).

Conclusion

CGRP-targeted preventives shifted migraine care from "borrowed" drugs with heavy side effects to purpose-built options that are better tolerated and now positioned as first-line. Injections and oral gepants give clinicians and patients a real choice. Talk to a clinician about whether your attack frequency, tolerability needs, and coverage make a CGRP preventive the right next step, and pair any decision with the broader neurological and chronic-condition library.